$NBRV News
Last published 3y ago
- 3y agoABUSBMYKRYSNBRVArbutus Appoints Two New ExecutivesGlobeNewswireKaren Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation
- 3y agoNBRVNabriva Therapeutics Provides Corporate UpdateGlobeNewswire-Company To Focus on Preserving Cash to Fund Orderly Wind Down of Operations- -Company To Continue Work With Torreya Capital On Asset Monetization- DUBLIN, Ireland, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nabriva
- 3y agoNBRVNabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisGlobeNewswire- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects – - Results Support Potential Utility of Lefamulin in Patients with Cystic Fibrosis - DUBLIN, Ireland and FORT WASHINGTON, Pa.,
- 4y agoNBRVNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateGlobeNewswire- Shifted Focus to SIVEXTRO to Enable Cost Cutting - - Cash Runway Extended into Q1 2023 - - Q3 2022 Total Revenue of $9.2 Million - - Engaged Torreya Capital As Strategic Advisor - - Conference call today at 4:30
- 4y agoNBRVNabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022GlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative
- 4y agoNBRVNabriva Therapeutics Announces Date of 1-for-25 Reverse Stock SplitGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious inf
- 4y agoNBRVNabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infec
- 4y agoNBRVNabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infect
- 4y agoNBRVNabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewswire-Net Product Sales of $8.7M Grew 25% versus Q2 2021- -SIVEXTRO Prescription Demand Grew 28% versus Q2 2021- -Conference Call Today at 4:30 p.m. Eastern Time- DUBLIN, Ireland, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:N
- 4y agoNBRVNabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022GlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infect
- 4y agoNBRVNabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim PharmaceuticalsGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infect
- 4y agoNBRVNabriva Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireDUBLIN, Ireland, May 13, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that
- 4y agoNBRVNabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateGlobeNewswire-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026- -SIVEXTRO Prescription Demand Grew 10% Versus Q1 2021- -Phase 1 XENLETA Cystic Fibrosis Trial Enrollment Progressing- -Conference Call Today
- 4y agoNBRVNabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026GlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infec
- 4y agoNBRVNabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022GlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infecti
- 4y agoNBRVNabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infec
- 4y agoNBRVNabriva Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate UpdateGlobeNewswire-Total revenue of $9.3 million driven by continued SIVEXTRO prescription growth- -Net product sales increased 8% sequentially in Q4 2021 versus Q3 2021- -Cash runway extended well into Q4 2022- -Conference call today at 4:30 p.m. Eastern Time-
- 4y agoNBRVNabriva Therapeutics to Report 2021 Financial Results and Recent Corporate Highlights on March 29, 2022GlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infec
- 4y agoNBRVNabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, Ireland, March 01, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced th
- 4y agoNBRVNabriva Therapeutics Adjourns Extraordinary General Meeting of Shareholders on January 18, 2022GlobeNewswire— Meeting to Reconvene on March 24, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innov
- 4y agoNBRVNabriva Therapeutics Adjourns Extraordinary General Meeting of ShareholdersGlobeNewswire— Meeting to Reconvene on January 18, 2022 — DUBLIN, Ireland and FORT WASHINGTON, Pa., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of in
- 4y agoNBRVNabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021GlobeNewswire-SIVEXTRO® (tedizolid phosphate) remains on track for return to historical peak sales by mid-2022- -XENLETA® (lefamulin) Phase I Cystic Fibrosis (CF) trial on track to enroll first patient in Q122- -Cash resources of $47.7 million as of 12/31/21
- 4y agoNBRVNabriva Therapeutics to Adjourn Extraordinary General Meeting of Shareholders on December 22, 2021GlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infec
- 4y agoNBRVNabriva Therapeutics to Present at the H.C. Wainwright BioConnect Virtual ConferenceGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infect
- 4y agoNBRVLefamulin NDA Filed in Mainland China for Treatment of Community Acquired PneumoniaGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infect
- 5y agoNBRVNabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral PackGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infect
- 5y agoNBRVNabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate UpdateGlobeNewswire-Revenues of $8.9 million increased 8% sequentially versus Q2 2021- -SIVEXTRO Net Sales & Prescriptions both grew 14% sequentially versus Q2 2021- -Cash runway extended to substantially through Q2 2022- -Conference call today at 4:30 p.m. Easter
- 5y agoNBRVNabriva Therapeutics to Present at the Jefferies London Healthcare ConferenceGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infect
- 5y agoNBRVNabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, Ireland, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced tha
- 5y agoNBRVNabriva Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Highlights on November 9, 2021GlobeNewswireDUBLIN, Ireland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced tha
- 5y agoNBRVNabriva Therapeutics to Present Data at CHEST Annual Meeting 2021GlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infect
- 5y agoNBRVNabriva Publishes Data Demonstrating the Potent Anti-Inflammatory Properties of XENLETA® (lefamulin)GlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infect
- 5y agoNBRVNabriva Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced tha
- 5y agoNBRVNabriva Therapeutics Appoints Dr. Christine Guico-Pabia, M.D., as Chief Medical OfficerGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infect
- 5y agoACXPCDTXCRMDITRM+5Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021PR NewswireWASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today announced that 10 of its member companies will presen
- 5y agoNBRVNabriva Therapeutics to Present Data at IDWeek 2021GlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infec
- 5y agoNBRVNabriva and Vizient Enter into Agreement to Make XENLETA® (lefamulin) Available to Vizient's Pharmacy Network ProgramGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infec
- 5y agoALTNBRVPENNWIMI+1Thinking about buying stock in Nabriva Therapeutics, WiMi Hologram Cloud, Xos Inc, Altimmune, or Penn National Gaming?PR NewswireNEW YORK, Sept. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NBRV, WIMI, XOS, ALT, and PENN. To
- 5y agoNBRVLefamulin Receives Approval in Taiwan for Treatment of Community-Acquired PneumoniaGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infec
- 5y agoNBRVNabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, Ireland, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced th
- 5y agoNBRVNabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infect
- 5y agoATHXAUPHNBRVSWCH+1Thinking about buying stock in Westport Fuel Systems, Switch, Athersys, Nabriva Therapeutics, or Aurinia Pharmaceuticals?PR NewswireNEW YORK, Aug. 6, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WPRT, SWCH, ATHX, NBRV, and AUPH. To
- 5y agoNBRVNabriva Therapeutics Reports Second Quarter 2021 Financial Results and Provides a Corporate UpdateGlobeNewswire-Revenues of $8.2 million driven by launch of own National Drug Code (NDC) for SIVEXTRO- -Cash runway substantially through Q1 2022- -Announced positive Phase 3 trial results for lefamulin in China, commercial rights assigned to Sumitomo Pharmaceut
- 5y agoACXPCDTXITRMNBRV+3Acurx Pharmaceuticals Joins the Antimicrobials Working GroupPR NewswireWASHINGTON, Aug. 5, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) (Acurx) to its coalition of companies with the mission to combat drug resistant infections and spur
- 5y agoNBRVNabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, Ireland, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced tha
- 5y agoNBRVNabriva Therapeutics to Report Second Quarter 2021 Financial Results and Recent Corporate Highlights on August 5, 2021GlobeNewswireDUBLIN, Ireland, July 22, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced tha
- 5y agoNBRVNabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireDUBLIN, Ireland, July 09, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced tha
- 5y agoCDTXITRMNBRVPRTK+2Crestone Joins Antimicrobials Working GroupPR NewswireWASHINGTON, June 8, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of Crestone, Inc. (Crestone) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations
- 5y agoHTGCNBRVNabriva Agrees to Extension of Principal Debt Repayments Under Existing Loan Agreement with Hercules CapitalGlobeNewswire- Principal Repayments Delayed At Least Until January 1, 2022 - Repayment Delay and Recent ATM Activity Extends Cash Runway Substantially Through the First Quarter of 2022 DUBLIN, Ireland and FORT WASHINGTON, Pa., June 03, 2021 (GLOBE NEWSW
- 5y agoNBRVNabriva Announces Changes to its Board of DirectorsGlobeNewswireDUBLIN, Ireland and FORT WASHINGTON, Pa., June 02, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infect